Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine

Journal of Infection

Volumn 50, Issue 3, 2005, Pages 262-264

  de Maat, Monique M R ^a   Beijnen, Jos H ^a,b   Schellens, Jan H M ^b,c   Mulder, Jan W ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; CLARITHROMYCIN; DIDANOSINE; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; NEVIRAPINE; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LYMPHOCYTE COUNT; MALE; PATIENT MONITORING; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CHRONIC DISEASE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE;

EID: 14944346065     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.02.011     Document Type: Article

References (12)

1. Van Heeswijk R.P.G. Veldkamp A.I. Mulder J.W. Meenhorst P.L. et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals AIDS 14 2000 F77-F82
2. Murphy T.L. Montaner J. Nevirapine: A review of its development, pharmacological profile and potential for clinical use Exp Opin Invest Drugs 5 1996 1183-1199
3. Montaner J.S.G. Reiss P. Cooper D. et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients JAMA 279 1998 930-937
4. Martinez E. Blanco J.L. Arnaiz J.A. et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy AIDS 15 2001 1261-1268
5. Naranjo C.A. Busto U. Sellers E.M. et al. A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 1981 239-245
6. Yew W.W. Chau C.H. Leung C.W. Cholestatic hepatitits in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection Clin Infect Dis 18 1994 1025-1026
7. Brown B.A. Wallace R.J. Griffith D.E. Girard W. Clarithromycin-induced hepatotoxicity Clin Infect Dis 20 1995 1073-1074
8. Wallace R.J. Brown B.A. Griffith D.E. Drug intolerance to high-dose clarithromycin among elderly patients Diagn Microbiol Infect Dis 16 1993 215-221
9. Robinson P, Gigliotti M, Lamson M, Azzam S, MacGregor T. Effect of the reverse transcriptase inhibitor, nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999. Abstract 374.
10. Carr A. Miller J. Law M. Cooper D.A. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction and associated with HIV nucleoside analogue therapy: A contribution to protease inhibitor-related lipodystrophy syndrome AIDS 14 2000 F25-F32
11. Miller K.D. Cameron M. Wood L.V. Dalakas M.C. Kovacs J.A. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases Ann Intern Med 133 2000 192-196
12. González de Requena D. Núñez M. Jimènez-Nàcher I. Soriano V. Liver toxicity caused by nevirapine AIDS 16 2002 290-291